As an entrepreneur-scientist, Dr. Bostian has held executive operating roles in companies financed by leading venture firms in the biotechnology arena, and has played advisory roles at the seed, pre-seed, and investment stage for numerous other organizations, securing over $275 million in financing from corporate partners and investors. Previous to VBS/Amalyte, he was a founder of Mpex Pharmaceuticals, a development-stage pharmaceutical company with discovery, preclinical and late clinical stage programs in the infectious disease arena, the founder and CEO of Iconix Pharmaceuticals, Inc., a pioneer and leader in the emerging field of chemogenomics, as well as founder and COO of Microcide Pharmaceuticals, Inc., a publicly traded company with clinical and pre-clinical programs, and one of the first biotech companies formed to focus on antibiotic resistant bacteria. Dr. Bostian was also previously Head of Microbiology and Molecular Genetics at Merck Research Laboratories where he was responsible for the discovery and development of new anti-microbial agents, as well as for the discovery of new leads from natural products for all of Merck's worldwide drug discovery programs. He is an inventor on numerous patents in drug discovery and genomics, and has led efforts resulting in a number of clinical candidates and commercial products.